BioCancell Therapeutics, Inc. is registered in Delaware, USA, and traded on the Tel Aviv Stock Exchange (TASE:BICL). To date, $10.5 million of non-diluting grants have been invested in research, as well as $14.5 million raised from private and public investors.

BioCancell is poised to move to a more aggressive development phase that will include several advanced clinical studies for BC-819 as well as next generation development with additional genes to broaden the scope of its platform, to be achieved through further fundraising or through strategic partnerships.

The underlying market potential of the indications BioCancell is developing is significant. With a cumulative patient base of over 200,000 new patients a year in the U.S. alone, sales are expected to be in the billions.

BioCancell's technology offers a well characterized, ubiquitous target, H19, present on a broad variety of tumors coupled with a precisely targeted production of DT-A toxin only in tumor cells resulting in an outstanding therapeutic index. The Company's strong IP position with worldwide filings, together with its large target markets and fast track opportunities, show great promise to investors and partners.